Wegovy and Cardiovascular Risk Reduction

Research brief

What the cardiovascular indication actually means

FDA cardiovascular indication for Wegovy

The U.S. Food and Drug Administration expanded Wegovy's indication on 8 March 2024. The approved use is to reduce the risk of cardiovascular death, myocardial infarction and stroke in adults with cardiovascular disease and either obesity or overweight. FDA also states that Wegovy should be used in addition to a reduced-calorie diet and increased physical activity.

The exact wording is important. The approval did not say that Wegovy prevents cardiovascular disease in every adult with obesity. The population already has cardiovascular disease. That makes this a secondary-prevention indication rather than a general primary-prevention indication. FDA: Wegovy cardiovascular indication.

SELECT Trial at a Glance

The New England Journal of Medicine report describes a mean treatment duration of about 33 months and mean follow-up of 39.8 months. The primary composite endpoint result corresponds to a 20% relative risk reduction. NEJM: SELECT cardiovascular outcomes trial.

What SELECT establishes

• Semaglutide 2.4 mg reduced the primary three-component MACE endpoint compared with placebo in the studied population.
• The studied population had established cardiovascular disease and overweight or obesity.
• Participants did not have diabetes at trial entry.
• The result supports cardiovascular-risk reduction beyond the traditional diabetes-only GLP-1 evidence base.
• The trial directly supports secondary cardiovascular prevention in the population studied.

What SELECT does not establish

• It does not establish the same cardiovascular benefit for people without established cardiovascular disease.
• It does not establish that every GLP-1 receptor agonist has the same cardiovascular effect.
• It does not mean every individual component of the composite endpoint independently met the same statistical superiority threshold.
• It does not prove that the cardiovascular effect is independent of all changes in weight, glycemia, inflammation or other biological pathways.
• It does not replace standard cardiovascular prevention or disease-management therapy.

Relative risk reduction versus absolute event difference

SELECT is frequently summarized as showing a 20% reduction in major cardiovascular events. That figure is the relative reduction associated with the hazard ratio of 0.80. The observed primary endpoint rates were 6.5% with semaglutide and 8.0% with placebo.

Those figures answer different questions. Relative measures describe proportional change between groups. Absolute event rates show the observed event burden in each group during the trial. Both are useful when interpreting clinical significance.

Why established cardiovascular disease matters

SELECT required preexisting cardiovascular disease. This makes the trial a secondary-prevention study: it asks whether treatment can reduce additional cardiovascular events in people who already have cardiovascular disease. That is different from primary prevention, which seeks to prevent first events in people who have not yet developed clinical cardiovascular disease.

Search queries such as “Wegovy heart benefits” can easily blur this distinction. For evidence interpretation, the correct question is not simply whether Wegovy has cardiovascular benefit. It is: cardiovascular benefit in which population, for which endpoint and under which regulatory indication?

Heart attack, stroke and cardiovascular death are part of a composite

The SELECT primary endpoint combined cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. The composite endpoint met the trial's superiority threshold. Cardiovascular death was the first confirmatory secondary endpoint, but it did not meet the prespecified significance threshold required within the hierarchical testing procedure. Because of that, formal superiority testing was not continued for the remaining confirmatory secondary endpoints.

This does not erase the primary MACE result. It means the statistically safest headline is the reduction in the primary composite endpoint rather than claiming separately proven superiority for every component. The distinction is important when writing evidence-led consumer health content.

How Wegovy fits into the broader GLP-1 cardiovascular story

Before SELECT, cardiovascular-outcomes evidence for GLP-1 receptor agonists was primarily associated with type 2 diabetes populations. Trials such as LEADER and SUSTAIN-6 helped establish cardiovascular risk reduction for selected medicines in high-risk diabetes populations. SELECT showed that semaglutide 2.4 mg could reduce MACE in a population without diabetes, provided those participants had established CVD and overweight or obesity.

This broader evidence base is reflected in current cardiovascular and CKM guidance, but drug-specific evidence should remain drug-specific. Wegovy is semaglutide 2.4 mg used in particular indications. Ozempic is also semaglutide, but it has a different approved-use framework and dose range. The same active ingredient does not make the brands interchangeable for regulatory claims.

Wegovy versus Ozempic for cardiovascular evidence

Does the cardiovascular benefit come only from weight loss?

SELECT demonstrated both weight reduction and fewer primary cardiovascular events with semaglutide, but the trial does not justify a simple claim that all cardiovascular benefit is caused by weight loss or, conversely, that it is fully independent of weight loss. Multiple pathways may contribute, including changes in adiposity, blood pressure, inflammation, metabolic status and other biological effects.

For a research site, the correct approach is to report the observed cardiovascular outcome and avoid overstating an unproven single mechanism.

Cardiovascular risk management remains broader than Wegovy

Even with an approved cardiovascular indication, Wegovy is not a substitute for the rest of cardiovascular prevention and treatment. Depending on the individual, evidence-based care may include lipid lowering, blood-pressure management, antiplatelet therapy when indicated, smoking cessation, physical activity, dietary changes and other disease-specific medications.

The 2026 cardiovascular-kidney-metabolic framework reinforces this integrated approach. A GLP-1-based therapy can contribute to risk reduction while remaining one part of a broader strategy.

Population Boundary Box

Key sources

• FDA: Wegovy cardiovascular risk-reduction indication
• NEJM: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
• GLP1Scientist: GLP-1 Cardiovascular Benefits
• GLP1Scientist: Wegovy research hub